Hims & Hers (HIMS) stock slides in premarket on weak Q1 outlook as SEC probe comes into view
Hims & Hers Health Inc. shares dropped 6.8% to $14.46 in premarket trading Tuesday after its first-quarter revenue forecast missed analyst estimates. The company disclosed an SEC investigation into its statements about compounded semaglutide products and cited ongoing regulatory scrutiny. Investors await management’s next update on March 2.